Public disclosure of inside information according to article 17 MAR
Arzneiwerk AG VIDA: No obligation to prepare consolidated financial statements
Berlin (pta060/17.04.2025/23:30 UTC+2)
Originally incorrect message / new, correctly corrected message:
Arzneiwerk AG Vida is no longer required to prepare consolidated financial statements for 2024, as its investment in EuroRX Arzneimittel GmbH no longer has to be consolidated. Consequently, costs for the preparation of the annual financial statements will also be saved. The key figures of EuroRX Arzneimittel GmbH will continue to be published.
About Arzneiwerk AG VIDA (ISIN DE000A289B07 / WKN A289B0):
Arzneiwerk AG VIDA is a specialized pharmaceutical supplier that ensures optimal pharmaceutical care for patients with a digitalized supply chain. Medicines for cancer, autoimmune deficiencies and combination therapies for personalized medicine are delivered quickly and reliably throughout Europe.
The need for indication-specific drugs is increasing across Europe and Arzneiwerk AG is benefiting from this growth. The European pharmaceutical market is a stable growth market and Arzneiwerk AG supplies predominantly German medicines with a high export share. Arzneiwerk AG is one of the largest specialty pharmacy companies in Germany.
(end)
| Emitter: |
Arzneiwerk AG VIDA Ordensmeisterstraße 15-16 12099 Berlin Germany |
|
|---|---|---|
| Contact Person: | Sascha Knoche | |
| Phone: | +49 170 8257343 | |
| E-Mail: | s.knoche@arzneiwerk.ag | |
| Website: | arzneiwerk.ag | |
| ISIN(s): | DE000A289B07 (Share) | |
| Stock Exchange(s): | Regulated Market in Frankfurt, Tradegate (Regulated Market); Free Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart |